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who initiated an episode of drug therapy between July 1994 and
December 31, 1999. Episodes were required to have a minimum
of 6 months of pre-treatment and 12 months of post-treatment
data. Episodes were then separated into three time periods: 
a “closed-access period” prior to October 1997, a “transition
period” covering the ﬁrst 6 months of open access, and an “open
access period” for episodes initiated after April 1, 1998. Multi-
variate regression models were used to estimate the impact of
open access on total health care costs and duration of therapy.
COX proportional hazard models were estimated for time to dis-
continuation. RESULTS: The number of patients re-starting drug
therapy or augmenting an existing therapy increased immedi-
ately with open access due to increased use of second-generation
medications. Episode initiation rates returned to pre-open access
levels within 6 months (transition period). Open access signiﬁ-
cantly reduced total costs primarily due to signiﬁcant savings in
nursing home care ($1700 and $1807 for re-starters and aug-
menters, respectively). However, drug persistence also declined
with open-access: 42 fewer days for re-starters and 33 fewer days
for augmenters. Augmenters and re-starters were 16% and 12%
more likely to discontinue therapy if their episodes were initiated
in the open access period. CONCLUSIONS: The decision to
include atypical antipsychotics by the Medi-Cal program
resulted in lower persistency of drug therapy and lower total
health care costs. Decision-makers and program administrators
must use caution in evaluating the impact of open access to new
antipsychotic medications on patient outcomes and costs.
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OBJECTIVES: Kleptomania involves stealing items that are not
needed or have limited value from shops, strangers and acquain-
tances. Its prevalence is estimated at 6 per 1000 U.S. adults.
Kleptomania appears to account for 5% of shoplifting. No con-
trolled trials of pharmacotherapy for kleptomania have been
published. We are conducting the ﬁrst controlled trial of a med-
ication for kleptomania. METHODS: We are enrolling adults
aged 20 and older with kleptomania of 1 year’s duration,
meeting DSM-IV criteria and marked by court referral or steal-
ing at least once per week. We exclude individuals with psychotic
disorders, alcohol or substance abuse, bipolar disorder or anti-
social personality disorder. Subjects receive open-label escitalo-
pram 10mg/day for 4 weeks and if not “much improved,” take
20mg/day for an additional 3 weeks. A “responder” is a patient
experiencing at least 50% decrease in the Y-BOCS-kleptomania
version (Y-BOCS-K) scale score and a CGI-I score of much or
very much improved. Responders are randomized double blind
to continue for four months on either escitalopram or placebo.
RESULTS: We have enrolled 13 patients of a planned 24. Eleven
completed the seven weeks of open-label escitalopram; two dis-
continued. The 11 completers include 9 women with a mean age
of 46 years. Nine are employed full-time, one unemployed and
one a student. Five are married, three single, three divorced. Ten
of the 11 received escitalopram 20mg/day. The completers’ mean
Y-BOCS-K score decreased from 23.1 (SD 5.1) to 8.6 (SD 7.8)
at end of week 7. On a 0–4 scale, the strength of urges to steal
decreased from a mean of 2.9 (SD 0.7) to 1.1 (SD 0.8). The mean
number of weekly urges to steal decreased from 3.0 (SD 0.6) to
1.6 (SD 1.1). Eight subjects were responders. Of these eight, four
relapsed during the 4-month double blind, placebo-controlled
phase, but the blind remains unbroken. CONCLUSIONS: Early
results suggest a therapeutic effect for escitalopram in treating
kleptomania.
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RISK OF REHOSPITALIZATION: OLANZAPINE 
VERSUS QUETIAPINE
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OBJECTIVE: To compare rehospitalization rates of individuals
with schizophrenia who had been treated and discharged on
olanzapine or quetiapine from acute care hospitals. METHODS:
Using Premier’s PerspectiveTM database—the largest U.S. hos-
pital drug utilization database, rehospitalization status was
examined for inpatients with schizophrenia (ICD9-CM: 295.xx)
that were successfully treated and discharged on olanzapine (N
= 7573) or quetiapine (N = 3368) between January 1999 and
September 2001. A successfully treated patient was one who
started treatment with olanzapine or quetiapine in hospital and
discharged on the same antipsychotic. Time to readmission up
to 33 months was analyzed by Kaplan-Meier models. Cox pro-
portional hazard models were used to derive the hazard ratio
(HR) for rehospitalization by adjusting potential confounding
factors. RESULTS: Overall rehospitalization rate in the study
population was 35.3%. After adjusting for potential confound-
ing factors, quetiapine therapy (average daily dose = 356.1mg)
was associated with 25% increased risk of rehospitalization
compared to olanzapine (average daily dose = 17.3mg) (HR =
1.25, 95% conﬁdence interval 1.17–1.34, p < 0.0001). Addi-
tionally, younger age, schizoaffective/paranoid diagnoses, higher
severity level, and urban hospital location were signiﬁcantly
associated with higher risk of readmission. CONCLUSIONS:
This study suggests that olanzapine-treated patients had lower
risk of rehospitalization than quetiapine-treated patients. More-
over, certain patient demographic/clinical factors and institution
characteristics also inﬂuenced hospital readmission.
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OBJECTIVE: Quetiapine’s relatively broad dosage guidelines
(150–750mg/day) may result in suboptimal dosing. This study
investigated the association between quetiapine dose levels and
efﬁcacy as reﬂected in mental health resource use by patients
with schizophrenia or bipolar disorder. METHODS: Patients
who initiated quetiapine monotherapy and were treated for at
least 4 months were identiﬁed in a large health plan database
(1999–2002). Use of mental health resources other than queti-
apine was measured by charges on all medical claims for mental
disorders (ICD-9-CM codes 290.xx–316.xx) and on all pre-
scription claims for other psychotropic medications. Each
patient’s ﬁrst quetiapine prescription was used to identify the
target daily dose, because subsequent adjustments may have rep-
resented an effect rather than a determinant of health resource
use, which was measured in months 2, 3, and 4 of treatment.
Regression models controlling for patient differences measured
associations between initial quetiapine dose and subsequent
mental health charges. A signiﬁcant negative association between
dose levels and mental health resource use may be an indicator
of suboptimal dosing. RESULTS: Patients with schizophrenia (N
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= 581) and bipolar disorder (N = 2421) received quetiapine
monotherapy for at least 4 months at mean initial daily doses of
237 (standard deviation [SD] = 198) mg and 147 (SD = 171) mg,
respectively. Both groups showed negative associations between
initial daily dose and subsequent mental health charges. For
schizophrenia, the relationship approached statistical signiﬁ-
cance (P = 0.1097), with a decrease of $1.28 in mental health
charges for each additional milligram of quetiapine. For bipolar
disorder, the relationship was statistically signiﬁcant (P =
0.0484), with a decrease of $1.31 per additional milligram.
CONCLUSION: This study shows that, in the treatment of
schizophrenia and bipolar disorder, higher doses of quetiapine
may lower levels of mental health resource use, suggesting
enhanced efﬁcacy.
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OBJECTIVES: To estimate the cost acceptability of conventional
antipsychotic (CA) compared to atypical antipsychotic (AA)
treatment for people with broadly deﬁned treatment-resistant or
treatment intolerant schizophrenia in the UK (poor clinical
response or side-effects to one or more antipsychotics, but not
considered for cocaine). METHODS: A total of 227 adults with
broadly deﬁned treatment resistant or intolerant schizophrenia
were enrolled into a pragmatic controlled trial of CA and AA
and randomised to a class of drug (CA or AA). The treating
physician and patient determined the choice of drug within the
class. A societal perspective was used; scheduled follow up was
12 months. The primary outcome was quality adjusted life years
(Daly’s) measured by the Aerosol and population utility tariffs.
Direct costs were measured as resource use multiplied by pub-
lished national unit costs. Censored data were predicted (Cox
regression) and missing observations imputed. Incremental cost
utility ratios (ICER), net beneﬁt statistic and cost acceptability
curves for the intent to teat cohort were calculated. Methods
related assumptions (link between costs and QALYS (stepwise
regression), association between Aerosol and clinical measures
(Spearman’s Rho), imputation method, source of unit costs) were
tested. RESULTS: Utility values were associated with clinical
measures (p < 0.00). QALY’s predicted costs (â = -0.21; p <
0.00). Primary and sensitivity analyses indicated a trend towards
QALY gain (0.04–0.08) and cost savings (£1100–£1200) for CA,
giving a net beneﬁt statistic of £5500 (2.5th–97.5th percentile: —
£2650–£13,000). Complete case analysis indicated a cost of
£3300/QALY. The probability that CA was cost-effective ranged
from 0.64 at a cost/QALY threshold of £0, to 0.78 at a
cost/QALY threshold of £20,000. CONCLUSIONS: The analy-
ses suggest CA is likely to be cost-effective in the UK in 64% of
cases if decision makers are not prepared to pay for an additional
QALY beneﬁt and 78% if they are prepared to pay up to
£20,000/QALY gained.
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OBJECTIVE: To assess the cost-effectiveness of long-acting
risperidone, oral risperidone (RIS), olanzapine (OLA) and
haloperidol decanoate (HAL-DEC) in patients with schizophre-
nia over a 1-year time period. METHODS: Published medical
literature, a consumer health database, and a clinical expert
panel were utilized to populate a decision tree model. The model
captured rates of compliance, relapse, frequency of relapse, dura-
tion of relapse, adverse events, resource utilization and unit cost
of health care resources. Outcomes are expressed in terms of per-
centage, number and duration of relapses per patient per year
and total cost per patient per treatment arm. RESULTS: The pro-
portion of patients predicted by the model to experience a relapse
requiring hospitalization in 1 year were 66% HAL-DEC, 41%
RIS and OLA, 26% long-acting risperidone, while the propor-
tion of patients with an exacerbation not requiring hospitaliza-
tion were 60% HAL-DEC, 37% RIS and OLA, and 24%
long-acting risperidone. The mean number of days of relapse
requiring hospitalization per patient per year were predicted to
be 28 HAL-DEC, 18 RIS and OLA, 11 long-acting risperidone,
while the mean number of days of exacerbation not requiring
hospitalization were 8 HAL-DEC, 5 RIS and OLA, and 3 long-
acting risperidone. This translates into cost savings with long-
acting risperidone compared to oral risperidone, olanzapine, and
haloperidol decanoate of $397, $1742, and $8328, respectively.
CONCLUSIONS: Predictive modeling suggests that long-acting
risperidone can potentially lead to lower rates and fewer days of
symptom exacerbation and hospitalization compared to alterna-
tive treatments. These lower rates translate into cost savings with
the use of long-acting risperidone.
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OBJECTIVE: To compare the utilization of health care resources
for patients with schizophrenia receiving olanzapine versus
risperidone treatment. METHOD: Schizophrenia patients were
drawn from North Carolina Medicaid Claims database. Treat-
ment groups were determined based on the ﬁrst use of olanzap-
ine or risperidone. The use of health care resources was estimated
for schizophrenia-related, mental health-related, and all-cause
services using the negative binomial regression models. The
models were controlled for patient demographic and clinical
characteristics, and resource utilization in the baseline period.
RESULTS: A total of 498 patients (286 in olanzapine cohort and
212 in risperidone cohort) were identiﬁed with available data for
three-month prior and 18-month after antipsychotic treatment.
During the 18-month post-treatment period, patients in olanza-
pine cohort had signiﬁcantly fewer hospital admissions (-0.36,
p = 0.047) and spent signiﬁcantly fewer days in the hospital 
(-0.92, p = 0.018) than risperidone patients for schizophrenia-
related conditions. There were no statistically signiﬁcant differ-
ences between the two cohorts in hospital admissions for mental
health-related and all-cause related conditions. The two groups
did not differ signiﬁcantly in terms of emergency room and
nursing home visits. In addition, patient demographic and clini-
cal characteristics, and resource utilization in prior treatment
period were also found to inﬂuence the use of the medical ser-
vices. CONCLUSIONS: Patients treated with olanzapine are
found to have both fewer hospital admissions and fewer hospi-
tal days for schizophrenia-related conditions as compared to
those treated with risperidone, indicating that olanzapine treat-
